European Hematology Association Congress (EHA)

home / conference / eha-congress
ALPINE Trial Points to Favorability of Zanubrutinib in Relapsed/Refractory CLL/SLL Versus Ibrutinib

ALPINE Trial Points to Favorability of Zanubrutinib in Relapsed/Refractory CLL/SLL Versus Ibrutinib

Ryan McDonald
June 11th 2021

Data from EHA 2021 showed that zanubrutinib was associated with better outcomes over ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Intensified Daratumumab Induction Leads to Promising Response in Ultra High–Risk Multiple Myeloma

Intensified Daratumumab Induction Leads to Promising Response in Ultra High–Risk Multiple Myeloma

Audrey Sternberg
June 11th 2021

Data from the OPTIMUM/MUKNINE trial presented at 2021 EHA Congress show promise for daratumumab plus CVRd as induction in patients with multiple myeloma and certain high-risk disease factors.

Cilta-cel Improved Responses and Survival Over SOC Regimens in Triple-Class Exposed Multiple Myeloma

Cilta-cel Improved Responses and Survival Over SOC Regimens in Triple-Class Exposed Multiple Myeloma

Matthew Fowler
June 11th 2021

The standard of care cohort comprised of patients across 3 global trials acted as a comparator for treatment with cilta-cel in patients with triple-class exposed multiple myeloma.

Immunosuppressive Anakinra Could Alleviate Toxicities of CAR T-Cell Therapy in Myeloma

Immunosuppressive Anakinra Could Alleviate Toxicities of CAR T-Cell Therapy in Myeloma

Jamie Cesanek
June 11th 2021

Further investigation will determine if initial results regarding the use of anakinra as prophylaxis for orvacabtagene autoleucel in multiple myeloma is efficacious enough for use in the real-world setting.

Ola Landgren, MD, PhD, on Frontline Standards With Daratumumab for Multiple Myeloma at EHA 2021

Ola Landgren, MD, PhD, on Frontline Standards With Daratumumab for Multiple Myeloma at EHA 2021

C. Ola Landgren, MD, PhD
June 11th 2021

CancerNetwork® sat down with Ola Landgren, MD, PhD, at the 2021 EHA Congress to talk about his presentation on first-line standard of care for multiple myeloma.

<1234